Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]

Jessica R. Bauman; Geoffrey Liu; Isabel Preeshagul; Stephen V. Liu; Barbara Melosky; Devin Abrahami; Benjamin Li; Despina Thomaidou; Kirsten Duncan; Stan Krulewicz; Martin Rupp; Jessica J. Lin

doi:10.1016/j.lungcan.2024.108000

Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]

Jessica R. Bauman, Geoffrey Liu, Isabel Preeshagul, Stephen V. Liu, Barbara Melosky, Devin Abrahami, Benjamin Li, Despina Thomaidou, Kirsten Duncan, Stan Krulewicz, Martin Rupp, Jessica J. Lin

Research output: Contribution to journal › Comment/debate

Abstract

The authors regret that in the Highlights section, the percentage indicating 42% needs to be updated to 44%. The authors would like to apologise for any inconvenience caused.

Original language	English
Article number	108000
Journal	Lung Cancer
Volume	197
DOIs	https://doi.org/10.1016/j.lungcan.2024.108000
State	Published - Nov 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.lungcan.2024.108000

Fingerprint

Dive into the research topics of 'Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]'. Together they form a unique fingerprint.

Cite this

Bauman, J. R., Liu, G., Preeshagul, I., Liu, S. V., Melosky, B., Abrahami, D., Li, B., Thomaidou, D., Duncan, K., Krulewicz, S., Rupp, M., & Lin, J. J. (2024). Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]. Lung Cancer, 197, Article 108000. https://doi.org/10.1016/j.lungcan.2024.108000

@article{7f9ec2671d2d453f8b1409b4e6fe8c19,

title = "Corrigendum to {"}Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer{"} [Lung Cancer 195 (2024) 107919]",

abstract = "The authors regret that in the Highlights section, the percentage indicating 42% needs to be updated to 44%. The authors would like to apologise for any inconvenience caused.",

author = "Bauman, {Jessica R.} and Geoffrey Liu and Isabel Preeshagul and Liu, {Stephen V.} and Barbara Melosky and Devin Abrahami and Benjamin Li and Despina Thomaidou and Kirsten Duncan and Stan Krulewicz and Martin Rupp and Lin, {Jessica J.}",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s)",

year = "2024",

month = nov,

doi = "10.1016/j.lungcan.2024.108000",

language = "English",

volume = "197",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

Bauman, JR, Liu, G, Preeshagul, I, Liu, SV, Melosky, B, Abrahami, D, Li, B, Thomaidou, D, Duncan, K, Krulewicz, S, Rupp, M & Lin, JJ 2024, 'Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]', Lung Cancer, vol. 197, 108000. https://doi.org/10.1016/j.lungcan.2024.108000

Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]. / Bauman, Jessica R.; Liu, Geoffrey; Preeshagul, Isabel et al.
In: Lung Cancer, Vol. 197, 108000, 11.2024.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]

AU - Bauman, Jessica R.

AU - Liu, Geoffrey

AU - Preeshagul, Isabel

AU - Liu, Stephen V.

AU - Melosky, Barbara

AU - Abrahami, Devin

AU - Li, Benjamin

AU - Thomaidou, Despina

AU - Duncan, Kirsten

AU - Krulewicz, Stan

AU - Rupp, Martin

AU - Lin, Jessica J.

PY - 2024/11

Y1 - 2024/11

N2 - The authors regret that in the Highlights section, the percentage indicating 42% needs to be updated to 44%. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that in the Highlights section, the percentage indicating 42% needs to be updated to 44%. The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85208024640&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2024.108000

DO - 10.1016/j.lungcan.2024.108000

M3 - Comment/debate

C2 - 39488462

AN - SCOPUS:85208024640

SN - 0169-5002

VL - 197

JO - Lung Cancer

JF - Lung Cancer

M1 - 108000

ER -

Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this